Prevention of de novo hepatitis B with adefovir dipivoxil in recipients of liver grafts from hepatitis B core antibody-positive donors

Liver Transplantation

Volumn 18, Issue 7, 2012, Pages 834-838

  Chang, Matthew S ^a   Olsen, Sonja K ^b   Pichardo, Elsa M ^a   Heese, Scott ^a   Stiles, Jessica B ^a   Abdelmessih, Rita ^a   Verna, Elizabeth C ^a   Guarrera, James V ^a   Emond, Jean C ^a   Brown, Robert S ^a  

^a Center for Liver Disease and Transplantation ^*  (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; CREATININE; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; TENOFOVIR;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION PREVENTION; LIVER GRAFT; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL;

EID: 84863943699     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23429     Document Type: Article

References (17)

1. Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995; 59: 230-234.
2. Avelino-Silva VI, D'Albuquerque LA, Bonazzi PR, Song AT, Miraglia JL, De Brito Neves A, Abdala E,. Liver transplant from anti-HBc-positive, HBsAg-negative donor into HBsAg-negative recipient: is it safe? A systematic review of the literature. Clin Transplant 2010; 24: 735-746.
3. Cholongitas E, Papatheodoridis GV, Burroughs AK,. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010; 52: 272-279.
4. Perrillo R,. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-Pacific transplant programs. Liver Transpl 2009; 15: 223-232.
5. Saab S, Waterman B, Chi AC, Tong MJ,. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transpl 2010; 16: 300-307.
6. Yen RD, Bonatti H, Mendez J, Aranda-Michel J, Satyanarayana R, Dickson RC,. Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor. Am J Transplant 2006; 6 (pt 1): 1077-1083.
7. Jain A, Orloff M, Abt P, Kashyap R, Mohanka R, Lansing K, et al. Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and lamivudine. Transplant Proc 2005; 37: 3187-3189.
8. Toniutto P, Fumo E, Caldato M, Apollonio L, Perin A, Pirisi M,. Favourable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation. Transplantation 2004; 77: 472-473.
9. Kim KK, Kim KH, Hwang S, Ahn CS, Moon DB, Ha TY, Lee SG,. Therapeutic effect of adefovir dipivoxil on recurrent or de novo infection of hepatitis B virus after liver transplantation: a preliminary report [in Korean]. Korean J Gastroenterol 2005; 45: 174-180.
10. Verna EC, Farrand ED, Elnaggar AS, Pichardo EM, Balducci A, Emond JC, et al. Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency. Transplantation 2011; 91: 1254-1260.
11. Chen YS, Wang CC, de Villa VH, Wang SH, Cheng YF, Huang TL, et al. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002; 16: 405-409.
12. Lee KW, Lee DS, Lee HH, Kim SJ, Joh JW, Seo JM, et al. Prevention of de novo hepatitis B infection from HbcAb-positive donors in living donor liver transplantation. Transplant Proc 2004; 36: 2311-2312.
13. Lee KH, Wai CT, Lim SG, Manjit K, Lee HL, Da Costa M, et al. Risk for de novo hepatitis B from antibody to hepatitis B core antigen-positive donors in liver transplantation in Singapore. Liver Transpl 2001; 7: 469-470.
14. Fontana RJ, Merion RM,. Are we ready for marginal hepatitis B core antibody-positive living liver donors? Liver Transpl 2003; 9: 833-836.
15. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS,. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999; 89: 14-18.
16. Bárcena Marugán R, García-Hoz F, Vázquez Romero M, Nash R, Mateos M, González Alonso R, et al. Prevention of de novo hepatitis B infection in liver allograft recipients with previous hepatitis B infection or hepatitis B vaccination. Am J Gastroenterol 2002; 97: 2398-2401.
17. Fontana RJ,. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49 (suppl): S185-S195.